Evidence map›Paper›PMID 36721423›Full record

ArticlePlasma processes and polymers (Print)2022

Oral SARS-CoV-2 reduction by local treatment: A plasma technology application?

Thomas von Woedtke, Gülsah Gabriel, Ulrich E Schaible, Sander Bekeschus

Abstract read
In one paragraph

Article in Plasma processes and polymers (Print), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Thomas von WoedtkeZIK Plasmatis, Leibniz Institute for Plasma Science and Technology (INP), a Member of the Leibniz Health Technologies Research Alliance Greifswald Germany.ORCID 0000-0002-1097-4832
Gülsah GabrielDepartment of Viral Zoonoses-One Health Leibniz Institute of Virology (LIV), A Member of the Leibniz Infections Research Alliance Hamburg Germany.
Ulrich E SchaibleDepartment of Cellular Microbiology Program Area Infections, Research Center Borstel, Leibniz Lung Center, A Member of the Leibniz Health Technologies and Leibniz Infections Research Alliances Parkallee Borstel Germany.
Sander BekeschusZIK Plasmatis, Leibniz Institute for Plasma Science and Technology (INP), a Member of the Leibniz Health Technologies Research Alliance Greifswald Germany.ORCID 0000-0002-8773-8862

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The SARS-CoV-2 pandemic reemphasized the importance of and need for efficient hygiene and disinfection measures. The coronavirus' efficient spread capitalizes on its airborne transmission routes via virus aerosol release from human oral and nasopharyngeal cavities. Besides the upper respiratory tract, efficient viral replication has been described in the epithelium of these two body cavities. To this end, the idea emerged to employ plasma technology to locally reduce mucosal viral loads as an additional measure to reduce patient infectivity. We here outline conceptual ideas of such treatment concepts within what is known in the antiviral actions of plasma treatment so far.

Indexed as

cold plasmadielectric barrier discharges (DBD)plasma jetplasma medicineSARS‐CoV‐2

Identifiers

PMID36721423
PMCPMC9880686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.